Quince Therapeutics (QNCX) Cash from Operations (2018 - 2026)

Quince Therapeutics has reported Cash from Operations for 9 years, with the latest figure at -$18.9 million in Q2 2026.

• On a quarterly basis, Cash from Operations fell 65.46% year-over-year to -$18.9 million in Q2 2026; TTM through Jun 2026 was -$46.9 million, a 30.97% decrease from a year earlier, with the FY2025 full-year figure at -$41.4 million, down 29.84% from the prior year.
• Cash from Operations was -$18.9 million for Q2 2026 at Quince Therapeutics, down from -$7.6 million in the prior quarter.
• The five-year high for Cash from Operations was -$3.6 million in Q1 2023, with the low at -$18.9 million in Q2 2026.
• Average Cash from Operations over 5 years is -$9.0 million, with a median of -$8.0 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Cash from Operations jumped 77.82% in 2023, then slumped 134.04% in 2024.
• Over 5 years, Cash from Operations stood at -$5.8 million in 2022, then slipped by 4.16% to -$6.1 million in 2023, then slipped by 24.25% to -$7.6 million in 2024, then sank by 38.78% to -$10.5 million in 2025, then sank by 80.2% to -$18.9 million in 2026.
• The last three Cash from Operations figures came in at -$18.9 million (Q2 2026), -$7.6 million (Q1 2026), and -$10.5 million (Q4 2025), per Business Quant data.